CRYSVITA® (burosumab-twza) addresses the underlying cause of XLH

CRYSVITA is an antibody that helps restore the balance of phosphorus in the body

Under normal conditions, a protein called fibroblast growth factor 23 (FGF23) helps maintain just the right amount of phosphorus in the body. When FGF23 works well, the extra phosphorus the body doesn’t need is eliminated in the urine, and a normal amount of phosphorus is retained in the blood.

In normal conditions, FGF23 activity helps the body maintain normal levels of phosphorus
In normal conditions, FGF23 activity helps the body maintain normal levels of phosphorus

Adults and children with XLH don’t have enough phosphorus because the activity of FGF23 in their bodies is abnormal. Without enough phosphorus, bones cannot grow or heal properly, leading to the symptoms of XLH.

In XLH, increased FGF23 activity leads to low levels of phosphorus in the body, causing bones to weaken
In XLH, increased FGF23 activity leads to low levels of phosphorus in the body, causing bones to weaken

CRYSVITA helps to keep a normal amount of phosphorus in the body by keeping FGF23 activity in check.

CRYSVITA® (burosumab-twza) can help block increased FGF23 activity and restore phosphorus levels back to normal
CRYSVITA® (burosumab-twza) can help block increased FGF23 activity and restore phosphorus levels back to normal